Research programme: targeted cancer diagnostics - Cancer Targeting Technology

Drug Profile

Research programme: targeted cancer diagnostics - Cancer Targeting Technology

Alternative Names: CTT-54

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Cancer Targeted Technology
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 05 Aug 2016 Preclinical development in Prostate cancer is underway in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in USA (Parenteral)
  • 05 May 2015 Cancer Targeted Technology receives SBIR grant from the National Institutes of health for development of targeted cancer diagnostics in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top